Reviews of therapeutics: Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes

Pharmacotherapy

Volumn 21, Issue 3 I, 2001, Pages 301-319

  Owens R C , Jr ^a  

^a MAINE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMITRIPTYLINE; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ASTEMIZOLE; CISAPRIDE; COTRIMOXAZOLE; DESIPRAMINE; DISOPYRAMIDE; DOFETILIDE; ENFLURANE; FLUCONAZOLE; GREPAFLOXACIN; HALOTHANE; IBUTILIDE; IMIPRAMINE; ISOFLURANE; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; NORTRIPTYLINE; PENTAMIDINE; PROCAINAMIDE; PROKINETIC AGENT; PYRROLE DERIVATIVE; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SOTALOL; TERFENADINE; UNINDEXED DRUG;

ASSAY; CARDIOTOXICITY; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; HEART ARRHYTHMIA; HEART MUSCLE POTENTIAL; HEART VENTRICLE ARRHYTHMIA; HUMAN; LONG QT SYNDROME; NONHUMAN; QT INTERVAL; REVIEW; RISK ASSESSMENT; STRUCTURE ACTIVITY RELATION; TORSADE DES POINTES; CHEMICALLY INDUCED DISORDER;

ANTI-INFECTIVE AGENTS; HUMANS; LONG QT SYNDROME; RISK ASSESSMENT; TORSADES DE POINTES;

EID: 0035293881     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.3.301.34206     Document Type: Review

References (127)

1. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions
2. QT-interval prolongation by non-cardiac drugs: Lessons to be learned from recent experience
3. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology
4. The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task force of the working group on arrhythmias of the European Society of Cardiology
5. Ventricular tachycardia with two variable opposing foci
6. How to measure the QT interval - What is normal?
7. Measurement of the QT interval and the risk associated with QTc interval prolongation: A review
8. The effects of reflex parasympathetic stimulation on the QT interval and QT dispersion
9. Beat-to-beat repolarization lability identifies patients at risk for sudden cardiac death
10. Diurnal pattern of QTc interval: How long is prolonged? Possible relation to circadian triggers of cardiovascular events
11. Measurement and interpretation of QT dispersion
12. Effects of antiarrhythmic drugs on QT interval dispersion - Relationship to antiarrhythmic action and proarrhythmia
13. Effect of coronary ischemia on QT dispersion
14. A common polymorphism associated with antibiotic-induced cardiac arrhythmia
15. The inherited long QT syndrome: From ion channel to bedside
16. Long QT syndromes and torsade de pointes
17. The QT interval and torsade de pointes
18. Terfenadine-ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences
19. Update: Clinically significant cytochrome P-450 drug interactions
20. Safety profile of grepafloxacin compared with other fluoroquinolones
21. Toxicity of quinolones
22. Experimental models of torsade de pointes
23. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome
24. Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: Distinguishing a drug effect from spontaneous variability
25. Accuracy of four automatic QT measurement techniques in cardiac patients and healthy subjects
26. Effects of the new class III antiarrhythmic drug dofetilide on the atrial and ventricular intracardiac monophasic action potential in patients with angina pectoris
27. The effects of erythromycin on the electrocardiogram
28. QT dispersion: Time for an obituary?
29. QT dispersion does not represent electrocardiographic interlead heterogencity of ventricular repolarization
30. Is QT interval prolongation harmful? A regulatory perspective
31. Comparative pharmacodynamic analysis of QT interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin
32. FDA/PhRMA task force to assess QT risk by pre-clinical markers
33. Electro-physiological mechanisms in a canine model of erythromycin-associated long QT syndrome
34. QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: A prospective evaluation and review of the literature
35. A review of erythromycin-induced malignant tachy-arrhythmia - Torsade de pointes. A case report
36. Erythromycin-induced long QT syndrome: Concordance with quinidine and underlying cellular electrophysiologic mechanism
37. The macrolides: Erythromycin, clarithromycin, and azithromycin
38. Intersubject and dose-related variability after intravenous administration of erythromycin
39. QT interval prolongation and torsades de pointes due to erythromycin lactobionate
40. Recent advances: The cytochrome P450 enzymes
41. Use of terfenadine and contraindicated drugs
42. Torsade de pointes: Mechanisms and management
43. QT prolongation and torsades de pointes associated with clarithromycin
44. Torsade de pointes induced by cisapride/clarithromycin interaction
45. Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin
46. QT interval prolonging drugs: Mechanisms and clinical relevance of the arrhythmogenic hazards
47. Clarithromycin associated with torsade de pointes
48. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers
49. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6)
50. Azithromycin and terfenadine: Lack of drug interaction
51. QT prolongation and paroxysmal ventricular tachycardia occurring during fever after trimethoprim-sulfamethoxazole administration
52. QT prolongation and torsade de pointes after administration of trimethoprim-sulfamethoxazole
53. Hypomagnesemic torsades de pointes
54. Torsade de pointes during administration of pentamidine isethionate
55. Recurrent ventricular tachycardia due to pentamidine-induced cardiotoxicity
56. Ventricular tachycardia due to pentamidine isethionate
57. Torsades de pointes during intravenous pentamidine isethionate therapy
58. Torsades de pointes associated with antimicrobial therapy for pneumonia
59. Ventricular tachycardia and torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome
60. Pentamidine-induced torsade de pointes
61. Pentamidine-induced torsades de pointes: Safe completion of therapy with inhaled pentamidine
62. Case report: Pentamidine and polymorphic ventricular tachycardia revisited
63. Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients
64. Effects of ketoconazole on QTc
65. Systemic antifungal agents. Drug interactions of clinical significance
66. Long QT syndrome and torsade de pointes in a patient receiving fluconazole
67. Fluconazole
68. Torsades de pointes after treatment with terfenadine and ketoconazole
69. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia
70. A case of pulmonary aspergillosis effectively treated with itraconazole. Possible interaction of the antimycotic agent with hydroquinidine
71. Syncopes during simultaneous use of terfenadine and itraconazole
72. Cardiac arrest associated with combination cisapride and itraconazole therapy
73. Combined use of astemizole and ketoconazole resulting in torsade de pointes
74. Fluoroquinolone toxicity profiles: A review focusing on newer agents
75. Comparative tolerability of the newer fluoroquinolone antibacterials
76. Inhibition of the HERG potassium ion channel by fluoroquinolone antibiotics: Correlation with the risk for clinically significant QT interval prolongation
77. Torsades de pointe probably related to sparfloxacin
78. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin
79. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia
80. Drugs. QT interval abnormalities and ventricular arrhythmias
81. Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers
82. Safety profile of sparfloxacin, a new fluoroquinolone antibiotic
83. QTc interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin
84. QTc prolongation associated with levofloxacin
85. Safety of trovafloxacin in treatment of lower respiratory tract infections
86. Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone
87. Safety and tolerabilitv of gatifioxacin, an advanced generation 8-methoxy fluoroquinolone
88. Assessment of the effect of gemifioxacin on QTc interval in healthy volunteers
89. Effect of single ascending, supratherapeutic doses of sparfloxacin on cardiac repolarization (QTc interval)
90. Pharmacokinetics of sparfloxacin in healthy volunteers and patients: A review
91. Effects of fluoroquinolones on HERG currents
92. Safety profile of the quinolones
93. Gatifloxacin vs. clarithromycin in the management of acute sinusitis
94. Treating community-acquired pneumonia with once-daily gatifloxacin vs. once-daily levofioxacin
95. Gatifloxacin treatment in patients with acute exacerbations of chronic bronchitis: Clinical trial results
96. Treating community-acquired pneumonia with once-daily gatifioxacin vs. twice-daily clarithromycin
97. Treating acute. Uncomplicated bacterial sinusitis with gatifloxacin
98. Gatifloxacin vs. cefuroxime axetil in patients with acute exacerbations of chronic bronchitis
99. Treating community-acquired pneumonia in hospitalized patients: Gatifloxacin vs. ceftriaxone/clarithromycin
100. A novel approach to postmarketing surveillance: The Tequin clinical experience study
101. Safety of gatifloxacin in patients with cardiovascular disease
102. Efficacy and safety of moxifloxacin vs. clarithromycin for community-acquired pneumonia
103. Safety update of moxifloxacin: A review of clinical trials and worldwide post-marketing surveillance
104. Quinolone-induced QT interval prolongation: A not-so-unexpected class effect
105. Moxifloxacin has a favorable cardiovascular safety profile in patients taking concomitant QTc prolonging drugs
106. Pharmacokinetics of fluoroquinolones in hepatic failure
107. Pharmacokinetics of quinolones in renal insufficiency
108. An overview of class III electrophysiological agents: A new generation of antiarrhythrnic therapy
109. QT-interval prolongation by non-cardiac drugs: Lessons to be learned from recent experience
110. A structural basis For drug-induced long QT syndrome
111. Structure-activity and structure-side-effect relationships for the quinolone antibacterials
112. Review of structure-toxicity relationships of fluoroquinolones
113. Quinolone structure-activity relationships
114. Specific toxicologic aspects of the quinolones
115. Variations on a theme: Cataloging human DNA sequence variation